{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:37:07Z","timestamp":1794001027153,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170195"],"award-info":[{"award-number":["82170195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170195"],"award-info":[{"award-number":["82170195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170195"],"award-info":[{"award-number":["82170195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170195"],"award-info":[{"award-number":["82170195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170195"],"award-info":[{"award-number":["82170195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma (MM) is an incurable hematologic malignancy. While recent therapies have significantly improved survival in MM patients, drug resistance and refractory phenomenon underscores the urgent need of new therapeutic targets. Methylenetetrahydrofolate dehydrogenase 2(MTHFD2) has been widely reported as a potential and promising anti-cancer target, but its role and underlying mechanisms remain unclear in MM. We aimed to investigate the biologic function and mechanisms of MTHFD2 in MM. First, we demonstrated that MTHFD2 is overexpressed in MM and associated with poor prognosis. We then illustrated that targeting MTHFD2 exhibits anti-MM effects in vitro and in vivo. Mechanistically, targeting MTHFD2 inhibited glycolysis and mitochondrial respiration in MM cells. For the nonmetabolic function of MTHFD2, we found that MTHFD2 knockdown affected the unfolded protein response (UPR) via decreasing expression of the splice form of X-box binding protein 1 (XBP1s). Importantly, the level of MTHFD2 in MM cells was associated with sensitivity of bortezomib, and targeting MTHFD2 synergizes with bortezomib against MM in vitro and in vivo. In summary, our innovative findings suggest that MTHFD2 is a promising target for MM, targeting it alters metabolic homeostasis of MM and synergizes with bortezomib to inhibit MM.<\/jats:p>","DOI":"10.1038\/s41420-025-02498-6","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:01:25Z","timestamp":1745578885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting MTHFD2 alters metabolic homeostasis and synergizes with bortezomib to inhibit multiple myeloma"],"prefix":"10.1038","volume":"11","author":[{"given":"Mingyuan","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6067-4088","authenticated-orcid":false,"given":"Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"2498_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"2498_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Prim. 2024;10:45.","journal-title":"Nat Rev Dis Prim"},{"key":"2498_CR3","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1007\/s00018-021-03756-3","volume":"78","author":"S Xiong","year":"2021","unstructured":"Xiong S, Chng WJ, Zhou J. Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma. Cell Mol Life Sci. 2021;78:3883\u2013906.","journal-title":"Cell Mol Life Sci"},{"key":"2498_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1182\/blood.2021013832","volume":"139","author":"C Panaroni","year":"2022","unstructured":"Panaroni C, Fulzele K, Mori T, Siu KT, Onyewadume C, Maebius A, et al. Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. Blood. 2022;139:876\u201388.","journal-title":"Blood"},{"key":"2498_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-017-0392-4","volume":"10","author":"Z Gu","year":"2017","unstructured":"Gu Z, Xia J, Xu H, Frech I, Tricot G, Zhan F. NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase. J Hematol Oncol. 2017;10:17.","journal-title":"J Hematol Oncol"},{"key":"2498_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cmet.2023.11.019","volume":"36","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Jian X, Chen S, An G, Jiang D, Yang Q, et al. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma. Cell Metab. 2024;36:159\u201375.e158.","journal-title":"Cell Metab"},{"key":"2498_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s10565-024-09904-2","volume":"40","author":"Y Wu","year":"2024","unstructured":"Wu Y, Luo Y, Yao X, Shi X, Xu Z, Re J, et al. KIAA1429 increases FOXM1 expression through YTHDF1-mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma. Cell Biol Toxicol. 2024;40:58.","journal-title":"Cell Biol Toxicol"},{"key":"2498_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33001","volume":"10","author":"H Huang","year":"2024","unstructured":"Huang H, Chen Y, Li Y, Zheng X, Shu L, Tian L, et al. Cytidine triphosphate synthase 1-mediated metabolic reprogramming promotes proliferation and drug resistance in multiple myeloma. Heliyon. 2024;10:e33001.","journal-title":"Heliyon"},{"key":"2498_CR9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936\u201345.","journal-title":"Blood"},{"key":"2498_CR10","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"2498_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:801\u201312.","journal-title":"Lancet Oncol"},{"key":"2498_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024;144:615\u201328.","journal-title":"Blood"},{"key":"2498_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2498_CR14","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196\u2013206.","journal-title":"N Engl J Med"},{"key":"2498_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2016.08.009","volume":"25","author":"GS Ducker","year":"2017","unstructured":"Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metab. 2017;25:27\u201342.","journal-title":"Cell Metab"},{"key":"2498_CR16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrc3557","volume":"13","author":"JW Locasale","year":"2013","unstructured":"Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. 2013;13:572\u201383.","journal-title":"Nat Rev Cancer"},{"key":"2498_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4128","volume":"5","author":"R Nilsson","year":"2014","unstructured":"Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014;5:3128.","journal-title":"Nat Commun"},{"key":"2498_CR18","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1128\/MCB.22.12.4158-4166.2002","volume":"22","author":"E Di Pietro","year":"2002","unstructured":"Di Pietro E, Sirois J, Tremblay ML, MacKenzie RE. Mitochondrial NAD-dependent methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase is essential for embryonic development. Mol Cell Biol. 2002;22:4158\u201366.","journal-title":"Mol Cell Biol"},{"key":"2498_CR19","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1126\/science.1218595","volume":"336","author":"M Jain","year":"2012","unstructured":"Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336:1040\u20134.","journal-title":"Science"},{"key":"2498_CR20","doi-asserted-by":"publisher","first-page":"2345455","DOI":"10.1080\/13510002.2024.2345455","volume":"29","author":"H-Y Mo","year":"2024","unstructured":"Mo H-Y, Wang R-B, Ma M-Y, Zhang Y, Li X-Y, Wen W-R, et al. MTHFD2-mediated redox homeostasis promotes gastric cancer progression under hypoxic conditions. Redox Rep. 2024;29:2345455.","journal-title":"Redox Rep"},{"key":"2498_CR21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/jnci\/djy160","volume":"111","author":"HQ Ju","year":"2019","unstructured":"Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, et al. Modulation of redox homeostasis by inhibition of MTHFD2 in colorectal cancer: mechanisms and therapeutic implications. J Natl Cancer Inst. 2019;111:584\u201396.","journal-title":"J Natl Cancer Inst"},{"key":"2498_CR22","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.1038\/s41388-019-0869-4","volume":"38","author":"NH Green","year":"2019","unstructured":"Green NH, Galvan DL, Badal SS, Chang BH, LeBleu VS, Long J, et al. MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma. Oncogene. 2019;38:6211\u201325.","journal-title":"Oncogene"},{"key":"2498_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1084\/jem.20151574","volume":"213","author":"Y Pikman","year":"2016","unstructured":"Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, et al. Targeting MTHFD2 in acute myeloid leukemia. J Exp Med. 2016;213:1285\u2013306.","journal-title":"J Exp Med"},{"key":"2498_CR24","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1111\/cas.15159","volume":"112","author":"X Liu","year":"2021","unstructured":"Liu X, Liu S, Piao C, Zhang Z, Zhang X, Jiang Y, et al. Non-metabolic function of MTHFD2 activates CDK2 in bladder cancer. Cancer Sci. 2021;112:4909\u201319.","journal-title":"Cancer Sci"},{"key":"2498_CR25","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1038\/s41388-018-0589-1","volume":"38","author":"T Nishimura","year":"2019","unstructured":"Nishimura T, Nakata A, Chen X, Nishi K, Meguro-Horike M, Sasaki S, et al. Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2. Oncogene. 2019;38:2464\u201381.","journal-title":"Oncogene"},{"key":"2498_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13046-022-02331-3","volume":"41","author":"R Zhao","year":"2022","unstructured":"Zhao R, Feng T, Gao L, Sun F, Zhou Q, Wang X, et al. PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2. J Exp Clin Cancer Res. 2022;41:125.","journal-title":"J Exp Clin Cancer Res"},{"key":"2498_CR27","doi-asserted-by":"publisher","first-page":"9946","DOI":"10.1073\/pnas.1334037100","volume":"100","author":"AH Lee","year":"2003","unstructured":"Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA. 2003;100:9946\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2498_CR28","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907\u201316.","journal-title":"Blood"},{"key":"2498_CR29","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1182\/blood.2020005795","volume":"136","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhao D, Xian M, Wang Z, Bi E, Su P, et al. MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Blood. 2020;136:2557\u201373.","journal-title":"Blood"},{"key":"2498_CR30","first-page":"3280","volume":"12","author":"T Kubicki","year":"2022","unstructured":"Kubicki T, Bednarek K, Kostrzewska-Poczekaj M, Luczak M, Lewandowski K, Gil L, et al. Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response. Am J Cancer Res. 2022;12:3280\u201393.","journal-title":"Am J Cancer Res"},{"key":"2498_CR31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nri2359","volume":"8","author":"DJ Todd","year":"2008","unstructured":"Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol. 2008;8:663\u201374.","journal-title":"Nat Rev Immunol"},{"key":"2498_CR32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0092-8674(01)00611-0","volume":"107","author":"H Yoshida","year":"2001","unstructured":"Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001;107:881\u201391.","journal-title":"Cell"},{"key":"2498_CR33","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1128\/MCB.23.21.7448-7459.2003","volume":"23","author":"AH Lee","year":"2003","unstructured":"Lee AH, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol. 2003;23:7448\u201359.","journal-title":"Mol Cell Biol"},{"key":"2498_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.40","volume":"6","author":"N Nikesitch","year":"2016","unstructured":"Nikesitch N, Tao C, Lai K, Killingsworth M, Bae S, Wang M, et al. Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response. Blood Cancer J. 2016;6:e432.","journal-title":"Blood Cancer J"},{"key":"2498_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","volume":"11","author":"DR Carrasco","year":"2007","unstructured":"Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco Daniel E, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007;11:349\u201360.","journal-title":"Cancer Cell"},{"key":"2498_CR36","doi-asserted-by":"publisher","first-page":"10204","DOI":"10.1021\/acs.jmedchem.9b01113","volume":"62","author":"J Kawai","year":"2019","unstructured":"Kawai J, Toki T, Ota M, Inoue H, Takata Y, Asahi T, et al. Discovery of a potent, selective, and orally available MTHFD2 inhibitor (DS18561882) with in vivo antitumor activity. J Med Chem. 2019;62:10204\u201320.","journal-title":"J Med Chem"},{"key":"2498_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/0008-5472.CAN-23-1290","volume":"84","author":"L Ramos","year":"2024","unstructured":"Ramos L, Henriksson M, Helleday T, Green AC. Targeting MTHFD2 to exploit cancer-specific metabolism and the DNA damage response. Cancer Res. 2024;84:9\u201316.","journal-title":"Cancer Res"},{"key":"2498_CR38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333.","journal-title":"Science"},{"key":"2498_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1033-z","volume":"18","author":"X-Y Chen","year":"2019","unstructured":"Chen X-Y, Zhang J, Zhu J-S. The role of m6A RNA methylation in human cancer. Mol Cancer. 2019;18:103.","journal-title":"Mol Cancer"},{"key":"2498_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0083-6729(08)00414-7","volume":"79","author":"KE Christensen","year":"2008","unstructured":"Christensen KE, Mackenzie RE. Mitochondrial methylenetetrahydrofolate dehydrogenase, methenyltetrahydrofolate cyclohydrolase, and formyltetrahydrofolate synthetases. Vitam Horm. 2008;79:393\u2013410.","journal-title":"Vitam Horm"},{"key":"2498_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","volume":"21","author":"X Chen","year":"2020","unstructured":"Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer. 2020;21:71\u201388.","journal-title":"Nat Rev Cancer"},{"key":"2498_CR42","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/nu11030608","volume":"11","author":"AM Mahmoud","year":"2019","unstructured":"Mahmoud AM, Ali MM. Methyl donor micronutrients that modify DNA methylation and cancer outcome. Nutrients. 2019;11:608.","journal-title":"Nutrients"},{"key":"2498_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/srep15029","volume":"5","author":"N Gustafsson Sheppard","year":"2015","unstructured":"Gustafsson Sheppard N, Jarl L, Mahadessian D, Strittmatter L, Schmidt A, Madhusudan N, et al. The folate-coupled enzyme MTHFD2 is a nuclear protein and promotes cell proliferation. Sci Rep. 2015;5:15029.","journal-title":"Sci Rep"},{"key":"2498_CR44","doi-asserted-by":"publisher","first-page":"5772","DOI":"10.1182\/blood-2011-07-366633","volume":"119","author":"N Mimura","year":"2012","unstructured":"Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, et al. Blockade of XBP1 splicing by inhibition of IRE1\u03b1 is a promising therapeutic option in multiple myeloma. Blood. 2012;119:5772\u201381.","journal-title":"Blood"},{"key":"2498_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22173-5","volume":"12","author":"M Shang","year":"2021","unstructured":"Shang M, Yang H, Yang R, Chen T, Fu Y, Li Y, et al. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation. Nat Commun. 2021;12:1940.","journal-title":"Nat Commun"},{"key":"2498_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215903","volume":"549","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Kiang KM, Li N, Liu J, Zhang P, Jin L, et al. Folate enzyme MTHFD2 links one-carbon metabolism to unfolded protein response in glioblastoma. Cancer Lett. 2022;549:215903.","journal-title":"Cancer Lett"},{"key":"2498_CR47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"2498_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.immuni.2021.10.011","volume":"55","author":"A Sugiura","year":"2022","unstructured":"Sugiura A, Andrejeva G, Voss K, Heintzman DR, Xu X, Madden MZ, et al. MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. Immunity. 2022;55:65\u201381.e69.","journal-title":"Immunity"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02498-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T12:03:56Z","timestamp":1745582636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02498-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2498"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02498-6","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All animal experiments were performed with the approval of the Ethics Committee for Animal Experimentation of Shanghai JiaoTong University School of Medicine. This study was approved by the Ruijin Hospital Ethics Committee of Shanghai JiaoTong University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"201"}}